Avience Biomedicals Ltd
- Market Cap ₹ 114 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 15.9
- Book Value ₹
- Dividend Yield %
- ROCE 34.2 %
- ROE 49.6 %
- Face Value ₹ 10.0
Pros
Cons
- Company might be capitalizing the interest cost
- Working capital days have increased from 49.5 days to 70.3 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 23.83 | 44.92 | |
| 19.65 | 33.40 | |
| Operating Profit | 4.18 | 11.52 |
| OPM % | 17.54% | 25.65% |
| 0.41 | 0.58 | |
| Interest | 0.94 | 1.45 |
| Depreciation | 0.62 | 0.88 |
| Profit before tax | 3.03 | 9.77 |
| Tax % | 28.71% | 27.33% |
| 2.16 | 7.10 | |
| EPS in Rs | 6.58 | 21.62 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 89% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 231% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 50% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 3.28 | 4.03 |
| Reserves | 2.94 | 18.63 |
| 15.13 | 22.16 | |
| 13.18 | 11.60 | |
| Total Liabilities | 34.53 | 56.42 |
| 10.25 | 13.10 | |
| CWIP | 0.03 | 4.62 |
| Investments | 0.03 | 0.03 |
| 24.22 | 38.67 | |
| Total Assets | 34.53 | 56.42 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 0.99 | 3.61 | |
| -4.03 | -8.81 | |
| 2.97 | 9.25 | |
| Net Cash Flow | -0.08 | 4.05 |
| Free Cash Flow | -2.84 | -4.71 |
| CFO/OP | 28% | 38% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 123.91 | 139.84 |
| Inventory Days | 290.31 | 176.30 |
| Days Payable | 129.94 | 98.06 |
| Cash Conversion Cycle | 284.29 | 218.07 |
| Working Capital Days | 28.64 | 70.29 |
| ROCE % | 34.18% |
Documents
Annual reports
No data available.